Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Share capital development

YearTransactionChange in number of sharesChange in share capital (SEK)Total number of sharesTotal share capital (SEK)Quota value per share (SEK)    
2006Formation100 000100 000100 000100 0001,00
2007New issue88 00088 000188 000188 0001,00
2008New issue18 80018 800206 800206 8001,00
2009New issue25 85025 850232 650232 6501,00
2010New issue68 66668 666301 316301 3161,00
2011Bonus issue-301 316301 316602 6322,00
2011New issue46 81393 626348 129696 2582,00
2011Split12 880 773-13 228 902696 2580,05
2011New issue7 018 873369 41420 247 7751 065 6720,05
2013New issue1 687 31488 80621 935 0891 154 4780,05
2014New issue1 687 31488 80623 622 4031 243 2840,05
2014New issue4 724 480248 65728 346 8831 491 9410,05
2015New issue/Warrants42 0002 21128 388 8831 494 1520,05
2016New issue20 277 7731 067 25248 666 6562 561 4040,05
2019New issue4 866 665256 14053 533 3212 817 5440,05
2020Share issue in kind63 773 3453 356 493117 306 6666 174 0380,05
2020New issue9 523 809501 253126 830 4756 675 2910,05
2020New issue38 238 0852 012 532165 068 5608 687 8220,05

Share capital

The share capital as of the last day of December 2020 amounted to SEK 8,687,822.18 divided into 165,068,560 shares with a quota value of approximately SEK 0.05 per share. The company has only issued shares of one class and all outstanding shares are fully paid. Egetis’ Articles of Association state that the share capital shall amount to a minimum of SEK 5,000,000 and a maximum of SEK 20,000,000 and that the number of shares shall amount to a minimum of 95,000,000 shares and a maximum of 380,000,000 shares. At a general meeting, each share entitles to one (1) vote. Each share gives an equal right to a share in the company’s assets and profit.

Calendar and upcoming reports

May 6, 2021
Erik Penser bank- Commercialization of pharmaceuticals

May 25, 2021
ABGSC Life Science Summit

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com